Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Commercial Sponsor
Apollomics Inc.
Summary
In the initial phase of this trial, eligible patients will be assigned to one of four dose levels (100mg, 200mg, 300mg or 400mg) of APL-101 administered over a 28-day cycle. In the second phase of this trial, eligible patients will receive a 400mg daily dose (200mg BID) of APL-101, as an oral capsule.